Clinical Trial Update: Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a combination immunotherapy (ipilimumab-nivolumab) with dendritic cell p53 vaccine in relapsed small cell lung cancer; trial terminated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• dendritic cell p53 vaccine (dendritic cell p53 vaccine)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Small Cell Lung Cancer, Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2023-03-30